123 employees
Our AI can prognosticate patient outcomes & personalize treatment in localized prostate cancer. Five Phase III randomized trials were used to develop prognostic and predictive AI biomarkers.
$20M sweet spot round size
$20M
from investors over 1 rounds
ArteraAI raised $20M on March 1, 2024